Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin.
Annexin A2 (p36) is a highly alpha-helical molecule that consists of two opposing sides, a convex side that contains the phospholipid-binding sites and a concave side, which faces the extracellular milieu and contains multiple ligand-binding sites. The amino-terminal region of annexin A2 extends along the concave side of the protein and contains the binding site for the S100A10 (p11) subunit. The interaction of these subunits results in the formation of the heterotetrameric form of the protein, annexin A2-S100A10 heterotetramer (AIIt). To simulate the orientation of AIIt on the plasma membrane we bound AIIt to a phospholipid bilayer that was immobilized on a BIAcore biosensor chip. Surface plasmon resonance was used to observe in real time the molecular interactions between phospholipid-associated AIIt or its annexin A2 subunit and the ligands, tissue-type plasminogen activator (t-PA), plasminogen, and plasmin. AIIt bound t-PA (Kd = 0.68 microm), plasminogen (Kd = 0.11 microm), and plasmin (Kd = 75 nm) with moderate affinity. Contrary to previous reports, the phospholipid-associated annexin A2 subunit failed to bind t-PA or plasminogen but bound plasmin (Kd = 0.78 microm). The S100A10 subunit bound t-PA (Kd = 0.45 microm), plasminogen (Kd = 1.81 microm), and plasmin (Kd = 0.36 microm). Removal of the carboxyl-terminal lysines from the S100A10 subunit attenuated t-PA and plasminogen binding to AIIt. These results show that the carboxyl-terminal lysines of S100A10 form t-PA and plasminogen-binding sites. In contrast, annexin A2 and S100A10 contain distinct binding sites for plasmin.
MacLeod
Travis J
TJ
Cancer Biology Research Group, Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
Kwon
Mijung
M
Filipenko
Nolan R
NR
Waisman
David M
DM
D017306:Annexin A2 / Q000737:chemistry* / Q000378:metabolism; D001665:Binding Sites; D015374:Biosensing Techniques; D002118:Calcium / Q000378:metabolism; D002135:Calcium-Binding Proteins / Q000737:chemistry* / Q000378:metabolism; D002460:Cell Line; D002478:Cells, Cultured; D019281:Dimerization; D005341:Fibrinolysin / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008239:Lysine / Q000737:chemistry; D010743:Phospholipids / Q000378:metabolism; D010958:Plasminogen / Q000378:metabolism; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D009418:S100 Proteins; D020349:Surface Plasmon Resonance; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014162:Transfection; D014471:Umbilical Veins / Q000166:cytology; D000099248:S100 Calcium Binding Protein A10
D017306:Annexin A2; D002118:Calcium; D002135:Calcium-Binding Proteins; D005341:Fibrinolysin; D008239:Lysine; D010743:Phospholipids; D010958:Plasminogen; D009418:S100 Proteins; D010959:Tissue Plasminogen Activator; D000099248:S100 Calcium Binding Protein A10